GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CKD Bio Corp (XKRX:063160) » Definitions » COGS-to-Revenue

CKD Bio (XKRX:063160) COGS-to-Revenue : 0.80 (As of Mar. 2025)


View and export this data going back to 2001. Start your Free Trial

What is CKD Bio COGS-to-Revenue?

CKD Bio's Cost of Goods Sold for the three months ended in Mar. 2025 was ₩33,834 Mil. Its Revenue for the three months ended in Mar. 2025 was ₩42,521 Mil.

CKD Bio's COGS to Revenue for the three months ended in Mar. 2025 was 0.80.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CKD Bio's Gross Margin % for the three months ended in Mar. 2025 was 20.43%.


CKD Bio COGS-to-Revenue Historical Data

The historical data trend for CKD Bio's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CKD Bio COGS-to-Revenue Chart

CKD Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.91 0.89 0.95 0.79

CKD Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.77 0.80 0.80 0.80

CKD Bio COGS-to-Revenue Calculation

CKD Bio's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=135813.521 / 171756.009
=0.79

CKD Bio's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=33833.921 / 42521.427
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CKD Bio  (XKRX:063160) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CKD Bio's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 33833.921 / 42521.427
=20.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


CKD Bio COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CKD Bio's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CKD Bio Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjeongno 3-ga, Seodaemun-gu, Seoul, KOR, 120-756
CKD Bio Corp is engaged in manufacturing and distribution of pharmaceutical materials and medicines. Its products portfolio include antibiotic, lactamase inhibitors, antituberculosis, antidiabetics, immunosuppressants, antihyperlipidemics, intermediates, and probiotics.

CKD Bio Headlines

No Headlines